1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Earnings Release
Annual Report to Security Holders
Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Investor Presentation
Financial Results, Press Release
Appoints Charles Newton to its Board of Directors
Announces Participation at Upcoming Healthcare Conferences
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer